For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease (PD).
New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.
SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...
A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback